What we're reading, March 31, 2016: the FDA changed guidelines for the use of the abortion pill, which could expand access; meanwhile Donald Trump isolated himself by saying women seeking abortion should face punishment; and drug makers are paying less fines for bad behavior.
A new change to the guidelines for the use of the abortion pill could increase access to a heavily restricted method of terminating a pregnancy. The FDA has approved a new label that lowers the recommended dosage to a drug used in medical abortion, and increases the time it can be used up to 3 weeks longer than before, reported The Washington Post. The new label still carries the old label’s warnings, which include the possibility of infection or death.
On the topic of abortion, Republican presidential candidate Donald Trump sparked outrage among both pro-life and pro-choice groups for a saying that women who seek abortion should face punishment. The New York Times reported that Trump later recanted, but the damage may have been done. Both Trump’s Republican rivals and pro-life advocates disavowed an effort to punish women choosing abortion.
Over the last 2 years there has been a noticeable drop in the amount of huge fines drug makers paid for bad behavior. A report found that in 2014 and 2015, pharmaceutical companies paid $2.8 billion to settle charges for various fraudulent practices, down considerably from $9.9 billion in 2012 and 2013, according to STAT. The worst offenders were Johnson & Johnson, Pfizer, Novartis, and GlaxoSmithKline. While the report has no explanation for the decline in penalties, there is speculation that the Department of Justice is pursuing different sorts of violations now.
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More